Lead counsel for Amneal Pharmaceuticals in AbbVie Inc. v. Amneal Pharms., a patent infringement dispute regarding AbbVie’s Norvir (Ritanovir).
Lead counsel for Amneal Pharmaceuticals in Amgen Inc. v. Amneal Pharms., a patent infringement dispute regarding Amgen’s Sensipar (Cinacalcet HCl).
Counsel for Amneal Pharmaceuticals in Alza Corp. et al. v. Amneal Pharms., a patent infringement dispute regarding Alza’s Concerta (Methylphenidate HCl).
Represented lead defendant, Amneal Pharmaceuticals, in Endo Pharms. et al. v. Amneal Pharms., et al, a 3-day Hatch-Waxman patent infringement trial before Judge Andrews in Federal District Court in Delaware. The case involved the validity of claims to oxymorphone hydrochloride, the active ingredient in Opana, with low levels of alpha, beta-unsaturated ketones. The case was tried July 11-13, 2016 and is pending in the trial court.
Lead counsel for Amneal Pharmaceuticals in Genzyme Corp. et al. v. Amneal Pharms., a patent infringement dispute regarding Sanofi/Genzyme’s Clolar (clofarabine injection).
Counsel to Collegium Pharmaceutical, Inc. in a series of related cases involving six patents owned by Purdue and related entities related to oxycodone. We obtained a judgment of invalidity of the three Orange Book listed patents in Purdue Pharma LP v. Collegium Pharm. case number MAD-1-15-cv-13099 on February 18, 2016, after succeeding in a motion to transfer the action from the District of Delaware to the District of Massachusetts.
Represented patent owner in 16 inter partes review proceedings relating to semiconductor fabrication technology.